Association between monoclonal antibody therapy, vaccination, and longer-term symptom resolution after acute COVID-19
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.COVID-19 vaccination, but not monoclonal antibody (mAb) therapy, shortened symptom recovery time. Both vaccination and mAb treatment reduced 28-day hospitalization risk in COVID-19 patients.
Area Of Science
- Infectious Diseases
- Immunology
- Public Health
Background
- Post-acute sequelae of COVID-19 (PASC) present a significant challenge due to a lack of effective therapies.
- Understanding factors influencing symptom recovery and hospitalization is crucial for managing the COVID-19 pandemic.
- Monoclonal antibody (mAb) treatments and COVID-19 vaccination are key interventions, but their impact on PASC symptom resolution requires further evaluation.
Purpose Of The Study
- To evaluate the association between monoclonal antibody (mAb) treatment or COVID-19 vaccination and symptom recovery in adults who tested positive for SARS-CoV-2.
- To assess the impact of these interventions on the time to symptom resolution and the risk of 28-day hospitalization.
Main Methods
- A longitudinal, survey-based cohort study was conducted from April 2021 to January 2022 across a multihospital health system.
- Included were 1612 adult participants (≥18 years) with a positive SARS-CoV-2 test.
- Primary exposures included mAb treatment and COVID-19 vaccination (≥2 doses); primary outcome was time to symptom resolution; secondary outcome was 28-day hospitalization.
Main Results
- Time to symptom resolution was similar between mAb-treated and untreated patients (aHR: 0.90).
- Patients receiving ≥2 COVID-19 vaccine doses experienced shorter symptom resolution times compared to unvaccinated individuals (aHR: 1.56).
- Both mAb therapy (aOR: 0.31) and ≥2 vaccine doses (aOR: 0.33) were associated with a significantly lower risk of 28-day hospitalization.
Conclusions
- COVID-19 vaccination is associated with accelerated symptom resolution following SARS-CoV-2 infection.
- Both mAb therapy and COVID-19 vaccination demonstrate a significant reduction in the risk of short-term hospitalization.
- Further research may explore optimizing treatment strategies for PASC and preventing severe outcomes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Overview
Vaccination is the administration of antigenic material from pathogens to confer immunity against a specific microorganism. Vaccination primes the immune system to recognize and mount an immune response faster and more effectively if the real pathogen is encountered. Vaccinations are one of the most efficient ways to protect both individual humans and the general public from disease. A growing anti-vaccination skepticism risks the successes of vaccination programs that helped reduce...
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Overview
The ability of a single antibody to recognize multiple structurally similar epitopes is an important immune defense strategy that enables the host to efficiently defend against many potentially threatening pathogens. However, cross-reactivity also elicits allergy symptoms against related allergens. It is increasingly important to understand the principles of cross-reactivity, as antibodies are actively being developed as therapeutic modalities for diverse diseases, including cancer.
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...